AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Net Income towards Common Stockholders came in at -$61.1 million in Q3 2025, down 132.34% year-on-year from $188.8 million in Q3 2024, and down 120.25% quarter-over-quarter from -$27.7 million in Q2 2025.
AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
AtaiBeckley's Net Income towards Common Stockholders history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 12.68% year-over-year to -$29.8 million; the TTM figure through Mar 2026 stood at -$56.2 million (changed N/A YoY), while the FY2025 annual figure was -$660.0 million, down 342.19% from the prior year.
- Net Income towards Common Stockholders came in at -$61.1 million for Q3 2025 at AtaiBeckley, down from -$27.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$26.4 million in Q1 2025 to a low of -$29.8 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$33.1 million (2023), against an average of -$31.1 million.
- Across the five-year window, Net Income towards Common Stockholders slumped 1190.93% in 2022 and surged 230.56% in 2023, its largest moves.
- AtaiBeckley's Net Income towards Common Stockholders stood at -$52.1 million in 2021, then advanced by 13.67% to -$45.0 million in 2022, then surged by 59.36% to -$18.3 million in 2023, then sank by 112.98% to -$39.0 million in 2024, then plunged by 56.77% to -$61.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$61.1 million (Q3 2025), -$27.7 million (Q2 2025), and -$26.4 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | -29.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.78 Mn |
| Sep 30, 2025 | -61.07 Mn |
| Jun 30, 2025 | -27.73 Mn |
| Mar 31, 2025 | -26.43 Mn |
| Mar 31, 2025 | -26.43 Mn |
| Dec 31, 2024 | -38.96 Mn |
| Sep 30, 2024 | -26.29 Mn |
| Jun 30, 2024 | -57.31 Mn |
| Mar 31, 2024 | -26.71 Mn |
| Dec 31, 2023 | -18.29 Mn |
| Sep 30, 2023 | 44.24 Mn |
| Jun 30, 2023 | -33.04 Mn |
| Mar 31, 2023 | -33.14 Mn |
| Dec 31, 2022 | -45.01 Mn |
| Sep 30, 2022 | -33.89 Mn |
| Jun 30, 2022 | -36.62 Mn |
| Mar 31, 2022 | -36.87 Mn |
| Dec 31, 2021 | -52.14 Mn |
| Sep 30, 2021 | -31.16 Mn |
| Jun 30, 2021 | -48.46 Mn |